EUVIMEDEUVIMED entdecken
Open Access

Engagement of the TCR against an oncolytic virus generates a population of effector CAR T cells with potent antitumor activity

Olivia Liseth iD, Elizabeth Appleton, Benjamin Kendall iD, Jill Thompson iD, Thanich Sangsuwannukul iD, Jason Tonne, Rosa Maria Diaz, Laura Evgin iD, Anton Patrikeev iD, Nicolas Sarbia iD, Shane Foo iD, Kevin Harrington iD und 3 weitere

Science Advances · 2026

DOI: 10.1126/sciadv.aef5331 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Olivia Liseth und 14 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Receptors, Antigen, T-Cell, Receptors, Chimeric Antigen, Oncolytic Viruses, T-Lymphocytes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health, Mayo Foundation for Medical Education and Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) T cell therapy faces many challenges against solid tumors including T cell exhaustion and poor CAR durability. Here, we show that engaging the CAR T cell endogenous T cell receptor (TCR) using an oncolytic virus enhances CAR T cell functionality, durability, and therapy. Upon combination therapy of solid tumors with CAR T cells and vesicular stomatitis virus (VSV), a subpopulation of antiviral, TCR-primed CAR T cells was generated with enhanced effector functions, altered activation states, and differential gene and protein expression when compared to non–TCR-primed CAR T cells. Single-cell RNA sequencing showed clonal expansion of anti-VSV CAR T cells and enhancement of effector-associated genes with VSV-mediated CAR T cell expansion. CD4 T cells played a pivotal role in the development of these TCR-primed CAR T cells. These results provide a strong rationale both for a novel use of systemic oncolytic virotherapy and for directly exploiting the CAR T cell TCR to fine tune the CAR T cell phenotype and function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Antigen, T-CellReceptors, Chimeric AntigenOncolytic VirusesT-LymphocytesImmunotherapy, AdoptiveNeoplasmsHumansAnimalsOncolytic VirotherapyLymphocyte ActivationCell Line, TumorMice

Substanzen

Receptors, Antigen, T-CellReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN, USA.
  • Medical Scientist Training Program, Mayo Clinic, Rochester, MN, USA.
  • Institute of Cancer Research, London, UK.
  • Imperial College London, London, UK.
  • Departments of Molecular Medicine and Immunology, Mayo Clinic, Rochester, MN, USA.
  • Medical Genetics Department, University of British Columbia, Vancouver, BC, Canada.

ORCID-Profile: Olivia Liseth, Benjamin Kendall, Jill Thompson, Thanich Sangsuwannukul, Laura Evgin, Anton Patrikeev, Nicolas Sarbia, Shane Foo, Kevin Harrington, Masahiro Ono, Alan Melcher, Richard Vile

Förderung

  • NCI NIH HHS
  • National Institutes of Health
  • Mayo Foundation for Medical Education and Research
  • Richard M. Schulze Family Foundation
  • Hyundai Hope On Wheels
  • British Skin Foundation
  • Shannon O’Hara Foundation
  • Joan Reece Chair of Immuno-oncology, King’s College, London

Zitieren

APA

Liseth, O., Appleton, E., Kendall, B., Thompson, J., Sangsuwannukul, T., Tonne, J., Diaz, R. M., Evgin, L., Patrikeev, A., Sarbia, N., Foo, S., Harrington, K., Ono, M., Melcher, A., & Vile, R. (2026). Engagement of the TCR against an oncolytic virus generates a population of effector CAR T cells with potent antitumor activity. Science Advances. https://doi.org/10.1126/sciadv.aef5331

Vancouver

Liseth O, Appleton E, Kendall B, Thompson J, Sangsuwannukul T, Tonne J, et al. Engagement of the TCR against an oncolytic virus generates a population of effector CAR T cells with potent antitumor activity. Science Advances. 2026. doi:10.1126/sciadv.aef5331

BibTeX
@article{Liseth2026,
  author = {Liseth, Olivia and Appleton, Elizabeth and Kendall, Benjamin and Thompson, Jill and Sangsuwannukul, Thanich and Tonne, Jason and Diaz, Rosa Maria and Evgin, Laura and Patrikeev, Anton and Sarbia, Nicolas and Foo, Shane and Harrington, Kevin and Ono, Masahiro and Melcher, Alan and Vile, Richard},
  title = {Engagement of the TCR against an oncolytic virus generates a population of effector CAR T cells with potent antitumor activity},
  journal = {Science Advances},
  year = {2026},
  doi = {10.1126/sciadv.aef5331}
}
Kostenlos starten →